{"id":2593,"date":"2025-10-13T23:15:28","date_gmt":"2025-10-13T14:15:28","guid":{"rendered":"http:\/\/172.207.84.36\/?page_id=2593"},"modified":"2025-12-04T14:55:05","modified_gmt":"2025-12-04T05:55:05","slug":"clinical","status":"publish","type":"page","link":"https:\/\/icrown.jihs.go.jp\/en\/research\/clinical\/","title":{"rendered":"\u200bResearch Utilizing iCROWN"},"content":{"rendered":"\n

Outcomes of Research Utilizing iCROWN<\/h2>\n\n\n\n

*The affiliations and job titles of the researchers are as of the time these studies were conducted.<\/p>\n\n\n\n

Development of Next-Generation Medical Infrastructures for Pandemics Involving Severe Acute Respiratory Infections: An Integrated Medical Care and Transport System Using AI and Real-Time Data<\/h3>\n\n\n\n
Principal Investigator<\/td>Nobuaki Shime, Hiroshima University<\/td><\/tr>
Research Overview<\/td>1) Development and analysis of an integrated SARI\/ARDS data platform
\u30fbThe platform covers SARI patients, primarily those with the most severe condition ARDS, and has expanded its scope to pediatric patients through the enhancement of EDC.
\u30fbThe platform has also integrated chest CT image data and long-term prognosis\/QOL (quality of life) data.
\u30fbIt has established a medical care database that covers Japan and is a system that can be easily linked to existing big data.
\uff12\uff09Development of a comprehensive medical care support system utilizing AI
\u30fbSeverity determination and remote medical care system: Utilizing patient data to predict the risk of aggravation and propose medical care plans to healthcare professionals.
\u30fbWide-area transport system for patients in critical condition: Proposes optimal transport destinations and methods based on real-time data of patient conditions, hospital bed occupancy, transportation availability, and other information.
\u30fbTransport monitoring system: Shares patient location, vital signs, and patient interaction records with the receiving hospital on a real-time basis.<\/td><\/tr>
Project status and other information<\/td>Ongoing
*This study was funded in FY2025 by the Japan Agency for Medical Research and Development\u2019s Research Program on Promoting Development of Innovative Drugs against Emerging and Re-emerging Infectious Diseases [Number of Publicly Offered Research\/Title of Publicly Offered Research and Development: 201 Study Contributing Towards Securing Medical Care Systems and the Promotion of Clinical Research for Emerging and Re-emerging Infectious Diseases].<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
<\/div><\/div>\n\n\n\n
View details<\/span><\/i><\/div><\/a><\/div>\n\n\n\n
<\/div><\/div>\n\n\n\n

Phase II Investigator-Initiated Clinical Trial to Evaluate the Efficacy and Safety of T-705 Injection (Favipiravir) in Combination with Oseltamivir for Influenza<\/h3>\n\n\n\n
Principal Investigator<\/td>Norio Ohmagari, Japan Institute for Health Security<\/td><\/tr>
Research Overview<\/td>An investigational drug (T-705IV) along with oseltamivir phosphate are administered for five days to influenza patients aged 65 or older requiring hospitalization to examine safety and efficacy.<\/td><\/tr>
Project status and other information<\/td>Ongoing
*This study was funded in FY2024 by the Japan Agency for Medical Research and Development\u2019s Research Program on Promoting Development of Innovative Drugs against Emerging and Re-emerging Infectious Diseases [Number of Publicly Offered Research\/Title of Publicly Offered Research and Development: 101 Research utilizing the Infectious disease Clinical Research netwOrk With National repository (iCROWN) (Research and development of therapeutics and diagnostics for priority infectious diseases)].<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
<\/div><\/div>\n\n\n\n
View details<\/span><\/i><\/div><\/a><\/div>\n\n\n\n
<\/div><\/div>\n\n\n\n

Study Assessing Correlations at Different Specimen Collection Sites Related to Severe Acute Respiratory Infections (SARI)<\/h3>\n\n\n\n
Principal Investigator<\/td>Nobuaki Matsunaga, Japan Institute for Health Security<\/td><\/tr>
Research Overview<\/td>Identification of challenges within the advancement of clinical research, such as centralized and unified ethics reviews, acquiring consent, specimen collection and transport, etc., to establish an efficient research framework. Assessment of saliva as an effective specimen for rapid diagnosis.<\/td><\/tr>
Project status and other information<\/td>Completed in FY2024
*This study was funded by the Japan Agency for Medical Research and Development\u2019s Research Program on Promoting Development of Innovative Drugs against Emerging and Re-emerging Infectious Diseases, specifically the Surveillance Research on Severe Acute Respiratory Infections (SARI) (23fk0108600j0101).<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
<\/div><\/div>\n\n\n\n
View details<\/span><\/i><\/div><\/a><\/div>\n\n\n\n
<\/div><\/div>\n\n\n\n

Research Contributing towards Developing Frameworks for Infectious Disease Crisis Management \"Scientific Knowledge on Domestically Approved Drugs for Post-Exposure Prophylaxis and Treatment of Highly Pathogenic Agents\"<\/h3>\n\n\n\n
Principal Investigator<\/td>Norihiro Kokudo, National Center for Global Health and Medicine<\/td><\/tr>
Research Overview<\/td>Scientific knowledge on post-exposure prophylaxis and treatment drugs for the Ebola virus disease (species Orthoebolavirus zairense, species Orthoebolavirus sudanense), Marburg disease, Lassa fever, Crimean-Congo hemorrhagic fever, South American Hemorrhagic Fevers, MERS, and SARS was organized and made public, providing information on drug names, formulations\/specifications, dosage, administration, along with efficacy and safety.
Scientific Knowledge on Domestically Approved Drugs for Post-Exposure Prophylaxis and Treatment of Highly Pathogenic Agents [PDF]<\/a><\/td><\/tr>
Project status and other information<\/td>Completed in FY2024
*This study was funded by the Health, Labour and Welfare Sciences Research Grant\/Health, Labour and Welfare Policy Research Grant for Research on Emerging and Re-Emerging Infectious Diseases and Vaccine Policy Promotion within the Disease and Disability Countermeasure Research Sector (24HA2018)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n
<\/div><\/div>\n\n\n\n
View details<\/span><\/i><\/div><\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

Here are the outcomes of research utilizing iCROWN (Infectious disease Clinical Research netwOrk With National repository) as well as the research project title, principal investigator, research content, and research funding are summarized below.<\/p>\n","protected":false},"author":8,"featured_media":224,"parent":2559,"menu_order":1,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_locale":"en_US","_original_post":"https:\/\/icrown.jihs.go.jp\/?page_id=95","footnotes":""},"class_list":["post-2593","page","type-page","status-publish","has-post-thumbnail","hentry","en-US"],"_links":{"self":[{"href":"https:\/\/icrown.jihs.go.jp\/wp-json\/wp\/v2\/pages\/2593","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/icrown.jihs.go.jp\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/icrown.jihs.go.jp\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/icrown.jihs.go.jp\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/icrown.jihs.go.jp\/wp-json\/wp\/v2\/comments?post=2593"}],"version-history":[{"count":11,"href":"https:\/\/icrown.jihs.go.jp\/wp-json\/wp\/v2\/pages\/2593\/revisions"}],"predecessor-version":[{"id":3234,"href":"https:\/\/icrown.jihs.go.jp\/wp-json\/wp\/v2\/pages\/2593\/revisions\/3234"}],"up":[{"embeddable":true,"href":"https:\/\/icrown.jihs.go.jp\/wp-json\/wp\/v2\/pages\/2559"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/icrown.jihs.go.jp\/wp-json\/wp\/v2\/media\/224"}],"wp:attachment":[{"href":"https:\/\/icrown.jihs.go.jp\/wp-json\/wp\/v2\/media?parent=2593"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}